However, mutations in IDH2 (OR: 0.52 [95%-CI: 0.31–0.86], p = 0.012) and CEBPA (OR: 0.59 [95%-CI: 0.35–0.98], p = 0.041) were associated with a decrease in the odds of EM AML. The gene discussed is IDH2; the disease is acute myeloid leukemia.